natgillin/translations-raw huggingface dataset:
Combination with strong P-gp or BCRP inhibitors should be avoided, or selection of an alternate concomitant medication with no or minimal potential to inhibit P-gp or BCRP is recommended.
Treba izbjegavati kombiniranje s jakim inhibitorima P-gp ili BCRP-a, ili se preporučuje odabir istodobne alternativne terapije lijekovima koji ne inhibiraju ili imaju minimalni potencijal za inhibiciju P-gp ili BCRP-a.
Combination with the most potent of the CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir) (see section 4.5).
Kombinacija s najsnažnijim inhibitorima CYP3A4 (npr. ketokonazolom, itrakonazolom, ritonavirom) (vidjeti dio 4.5).
Combination with TNF antagonists
Kombinacija s antagonistima faktora nekroze tumora (TNF)
Combination with two inducers has not been studied.
Kombinacija s dva induktora nije ispitivana.
Combination with verapamil or diltiazem which are moderate CYP3A4 inhibitors with heart rate reducing properties (see section 4.5)
Istodobna primjena s verapamilom ili diltiazemom koji su umjereni inhibitori CYP3A4 s učinkom na smanjenje srčane frekvencije (vidjeti dio 4.5)
combination with Viekirax without dasabuvir.
kombinaciji s lijekom Viekirax bez dasabuvira.
Combination with xanthine oxidase inhibitors
Kombinacija s inhibitorima ksantin oksidaze
combination.
kombinaciji.
Combinations containing Victoza were more effective at controlling blood glucose than combinations without the medicine.
Kombinacije koje sadrže lijek Victozu bile su djelotvornije u kontroli glukoze u krvi od kombinacija bez tog lijeka.
Combinations contraindicated (see section 4.3): Cisapride, erythromycin intravenous (IV), toremifene, mizolastine, moxifloxacin, arsenic, Class IA and III antiarrhythmics
Kombinacije koje su kontraindicirane (vidjeti dio 4.3): cisaprid, eritromicin intravenski (i.v.) , toremifen, mizolastin, moksifloksacin, arsen, antiaritmici skupine IA i III
Combinations contraindicated (see section 4.3): Cisapride, erythromycin intravenous (IV), toremifene, mizolastine, moxifloxacin, arsenic, Class IA and III antiarrhythmics
Kombinacije koje su kontraindicirane (vidjeti dio 4.3): cisaprid, eritromicin intravenski (i.v.), toremifen, mizolastin, moksifloksacin, arsen, antiaritmici skupine IA i III
Combinations not recommended: Methadone, haloperidol, amisulpride, chlorpromazine, sulpiride, zuclopenthixol, halofantrine, pentamidine and lumefantrine.
Kombinacije koje se ne preporučuju: metadon, haloperidol, amisulprid, klorpromazin, sulpirid, zuklopentiksol, halofantrin, pentamidin i lumefantrin.
Combinationswith other treatments
Kombinacija s ostalim načinima liječenja
Combine the medicine.
Pomiješajte lijek.
Combined
Kombinirani
Combined
Zbirni podaci
Combined asthma-related death or life-threatening experience
Kombinirano smrt ili životno ugrožavajući događaj povezani s astmom
Combined dose groups
Skupine s kombiniranim
Combined HAB vaccine (360/10)
Kombinirano HAB cjepivo (360/10)
Combined hormonal contraceptives and cancer Cervical cancer
Kombinirani hormonski kontraceptivi i rak Rak grlića maternice
Combined low platelet, red, and white blood cell count
manjen ukupni broj crvenih i bijelih krvnih stanica i krvnih pločica
combined oral contraceptives (e.g. ethinylestradiol, norgestimate)
kombinirane kontracepcijske tablete koje se uzimaju na usta (npr. etinilestradiol, norgestimat)
Combined Phase 1 pharmacokinetic data at nelarabine doses of 104 to 2,900 mg/m2 indicate that mean (%CV) clearance (Cl) values for nelarabine are 138 l/h/m2 (104 %) and 125 l/h/m2 (214 %) in adult and paediatric patients, respectively, on day 1 (n = 65 adults, n = 21 paediatric patients).
Podaci o farmakokinetici nelarabina primijenjenoga u dozi od 104 do 2900 mg/m2, iz ispitivanja faze I, ukazuju na to da 1. dana terapijskoga ciklusa prosječne (%CV) vrijednosti klirensa (Cl) nelarabina u odraslih bolesnika iznosi 138 l/h/m2 (104%), a u pedijatrijskih bolesnika 125 l/h/m2 (214%) (n = 65 odraslih bolesnika, n = 21 pedijatrijski bolesnik).
Combined Phase 1 pharmacokinetic data at nelarabine doses of 104 to 2,900 mg/m2 indicate that the clearance (Cl) and Vss values for nelarabine and ara-G are comparable between the two groups.
Farmakokinetički podaci o nelarabinu primijenjenom u dozi od 104 do 2900 mg/m2 dobiveni u ispitivanjima faze I, pokazuju da su usporedive vrijednosti klirensa (Cl) i Vss vrijednosti nelarabina i ara-G, zabilježene u obje ispitivane skupine.
Combined Responses (CR+sCR+VGPR) n (%)
Objedinjeni odgovori (CR+sCR+VGPR) n (%)
Combined studies 1 & 2
Skupni rezultati ispitivanja 1 & 2
Combined term that includes atrial fibrillation, atrial flutter, atrioventricular block, bundle branch block, sick sinus syndrome, bradycardia, and tachycardia
Kombinirani termin koji uključuje fibrilaciju atrija, undulaciju atrija, atrioventrikularni blok, blok grane, sindrom bolesnog sinusa, bradikardiju i tahikardiju
Combined use with peginterferon alfa–2a as compared to alfa–2b:
Kombinacija s peginterferonom alfa–2a u usporedbi s alfa–2b:
Combined use with peginterferon alfa–2a see specific section in section 4.4.
Za primjenu s peginterferonom alfa–2a vidjeti odgovarajući odjeljak u dijelu 4.4.
combined with clinical covariates) could be used to predict overall survival
genetički/genomski markeri (sami ili u kombinaciji s kliničkim kovarijatama)
Combining both studies, the overall response rate at the time of analysis was 66% (263 out of 398 patients) and preliminary data suggest that the average length of response was 8.5 months.
Uzimajući u obzir oba ispitivanja, ukupna stopa odgovora na liječenje u trenutku analize bila je 66 % (263 od 398 bolesnika), a preliminarni podaci ukazuju na to da je prosječno trajanje odgovora bilo 8,5 mjeseci.
Combining the results of controlled clinical trials, more cases of NMSC were observed in patients receiving Enbrel compared with control patients, particularly in patients with psoriasis.
Kombiniranjem rezultata kontroliranih kliničkih ispitivanja Enbrela primijećeno je više slučajeva NMSC u bolesnika koji su dobivali Enbrel u usporedbi s bolesnicima u kontrolnoj skupini, posebno u bolesnika sa psorijazom.
Combining this medicine with alcohol is not recommended.
Ne preporučuje se kombinirati ovaj lijek s alkoholom.
Combivir 150 mg/300 mg film-coated tablets
Combivir 150 mg/300 mg filmom obložene tablete
Combivir 150 mg/300 mg film-coated tablets Lamivudine/zidovudine
Combivir 150 mg/300 mg filmom obložene tablete lamivudin/zidovudin
Combivir 150 mg/300 mg tablets Lamivudine/zidovudine
Combivir 150 mg/300 mg tablete lamivudin/zidovudin
Combivir contains lamivudine and zidovudine, therefore any interactions identified for these individually are relevant to Combivir.
Combivir sadrži lamivudin i zidovudin, stoga bilo koja uočena interakcija za individualne komponente je relevantna i za Combivir.
Combivir is a fixed dose combination of lamivudine and zidovudine
Combivir je fiksna kombinacija lamivudina i zidovudina
COMBO I study
Ispitivanje COMBO I
COMETRIQ 20 mg capsules are grey and have “XL184 20mg” printed on one side.
COMETRIQ kapsule od 20 mg su sive boje i imaju oznaku “XL184 20mg” utisnutu s jedne strane.
COMETRIQ 20 mg hard capsules COMETRIQ 80 mg hard capsules Cabozantinib
COMETRIQ 20 mg tvrde kapsule COMETRIQ 80 mg tvrde kapsule kabozantinib
COMETRIQ 20 mg hard capsules COMETRIQ 80 mg hard capsules Cabozantinib (S)-malate
COMETRIQ 20 mg tvrde kapsule COMETRIQ 80 mg tvrde kapsule kabozantinib (S)-malat
Cometriq has been given ‘conditional approval’.
Za lijek Cometriq izdano je „uvjetno odobrenje”.
Comfortis 1040 mg 1040 mg spinosad
Comfortis 1040 mg 1040 mg spinosada
Comfortis 140 mg 140 mg spinosad
Comfortis 140 mg 140 mg spinosada
Comfortis 1620 mg 1620 mg spinosad
Comfortis 1620 mg 1620 mg spinosada
Comfortis 1620 mg spinosad 1620 mg For the full list of excipients, see section 6.1.
Comfortis 1620 mg spinosad 1620 mg Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
Comfortis 180 mg 180 mg spinosad
Comfortis 180 mg 180 mg spinosada
Comfortis 270 mg 270 mg spinosad
Comfortis 270 mg 270 mg spinosada
Comfortis 425 mg 425 mg spinosad
Comfortis 425 mg 425 mg spinosada
Comfortis 665 mg 665 mg spinosad
Comfortis 665 mg 665 mg spinosada
Comfortis 90 mg 90 mg spinosad
Comfortis 90 mg 90 mg spinosada
Comfortis 90 mg chewable tablets for dogs and cats Comfortis 140 mg chewable tablets for dogs and cats Comfortis 180 mg chewable tablets for dogs and cats Comfortis 270 mg chewable tablets for dogs and cats Comfortis 425 mg chewable tablets for dogs and cats Comfortis 665 mg chewable tablets for dogs Comfortis 1040 mg chewable tablets for dogs Comfortis 1620 mg chewable tablets for dogs
Comfortis 90 mg tablete za žvakanje za pse i mačke Comfortis 140 mg tablete za žvakanje za pse i mačke Comfortis 180 mg tablete za žvakanje za pse i mačke Comfortis 270 mg tablete za žvakanje za pse i mačke Comfortis 425 mg tablete za žvakanje za pse i mačke Comfortis 665 mg tablete za žvakanje za pse Comfortis 1040 mg tablete za žvakanje za pse Comfortis 1620 mg tablete za žvakanje za pse
Commercially manufactured oseltamivir powder for oral suspension (6 mg/ml) is the preferred product for paediatric and adult patients who have difficulties swallowing capsules or where lower doses are needed.
Tvornički proizveden Ebilfumin prašak za oralnu suspenziju (6 mg/ml) je proizvod kojem se daje prednost kod pedijatrijskih i odraslih bolesnika koji imaju poteškoća s gutanjem kapsula, ili ako su potrebne manje doze lijeka.
Commercially manufactured oseltamivir powder for oral suspension (6 mg/ml) is the preferred product for paediatric and adult patients who have difficulties swallowing capsules or where lower doses are needed.
Tvornički proizveden oseltamivir prašak za oralnu suspenziju (6 mg/ml) je proizvod kojem se daje prednost kod pedijatrijskih i odraslih bolesnika koji imaju poteškoća s gutanjem kapsula, ili ako su potrebne manje doze lijeka.
Commercially manufactured oseltamivir powder for oral suspension (6 mg/ml) is the preferred product for paediatric and adult patients who have difficulties swallowing capsules or where lower doses are needed.
Tvornički proizvedeni prašak oseltamivira za oralnu suspenziju (6 mg/ml) proizvod kojem se daje prednost kod pedijatrijskih i odraslih bolesnika koji imaju poteškoća s gutanjem kapsula, ili ako su potrebne manje doze lijeka.
Commercially manufactured Tamiflu for oral suspension (6 mg/ml) is the preferred product for paediatric and adult patients who have difficulties swallowing capsules or where lower doses are needed.
Tvornički proizveden Tamiflu prašak za oralnu suspenziju (6 mg/ml) je proizvod kojem se daje prednost kod pedijatrijskih i odraslih bolesnika koji imaju poteškoća s gutanjem kapsula, ili ako su potrebne manje doze lijeka.
Commercially manufactured Tamiflu for oral suspension (6mg/ml) is the preferred product for paediatric and adult patients who have difficulties swallowing capsules or where lower doses are needed.
Tvornički proizveden Tamiflu prašak za oralnu suspenziju (6 mg/ml) je proizvod kojem se daje prednost kod pedijatrijskih i odraslih bolesnika koji imaju poteškoća s gutanjem kapsula, ili ako su potrebne manje doze lijeka.
Common
Bupropion
Common
edem plućaa
Common
flebitis
common
hipoestezija
common
Kombinacija
Common
kožni vaskulitis
Common
lakrimalnog
Common
manje često
common
metforminom
Common
Mišićni spazmi
Common
Nepoznato
Common
nokturija
common
Nuspojava
Common
Opioidi
Common
Plodnost
common
povišena laktična
common
proljev
Common
redoprsja
Common
Stevens
common
težina6
Common
usta, disfagija,
Common
ustav
Common
uveitis
Common
Vrlo rijetko
Common
Vrlo često
Common
Vrlo često Često
Common
zatvor
Common
Ćesto:
Common
Ĉesto
Common
Često
Common
Često alopecija
Common
Često Glavobolja
Common
Često infekcija
Common
Često Manje često
Common
Često Metalni okus
Common
Često Mučnina
Common
Često Omaglica
Common
Često osipi
Common
Često Često
Common
Često:
common
česte
Common
često
common
često manje često
Common ( may affect up to 1 in 10 people)
Često (mogu se javiti u do 1 na 10 osoba)
Common ( may affect up to 1 in 10 people):
Često (mogu se javiti u manje od 1 na 10 osoba):
Common ( ≥ 1/100 to < 1/10): Bradycardia with or without hypotension or syncope, tachycardia.
Često ( ≥ 1/100 i < 1/10): bradikardija sa ili bez hipotenzije ili sinkope, tahikardija
Common (  1/100 to
Često ( 1/100 i
Common (2.7%)d
Često (2,7%)d
Common (>1/100, <1/10): injection site redness, injection site swelling, injection site induration, injection site ecchymosis and injection site pain, fever, malaise, fatigue and shivering
Često (>1/100 i <1/10): crvenilo na mjestu injekcije, oteknuće na mjestu injekcije, otvrdnuće na mjestu injekcije, ekimoza i bol na mjestu injekcije, vrućica, malaksalost, umor i tresavica
Common (>1/100, <1/10): injection site redness, injection site swelling, injection site induration, injection site ecchymosis and injection site pain, fever, malaise, fatigue and shivering
Često (>1/100 i <1/10): crvenilo na mjestu injekcije, oteknuće na mjestu injekcije, otvrdnuće na mjestu injekcije, ekimoza i bol na mjestu injekcije, vrućica, opća malaksalost, umor i tresavica
common (>1/100, <1/10): recurrent ischaemia, cardiac failure, myocardial infarction, cardiogenic shock, pericarditis, pulmonary oedema
često (>1/100 i <1/10): recidivirajuća ishemija, zatajenje srca, infarkt miokarda, kardiogeni šok, perikarditis, plućni edem
Common (affects 1 to 10 in 100 vaccinees):
Često (može se javiti u 1 do 10 na 100 cijepljenih):
Common (affects 1 to 10 users in 100)
Često (javlja se kod 1 do 10 na 100 korisnika)
Common (affects 1 to 10 users in 100)
Često (pojavljuje se kod 1 do 10 korisnika na 100)
common (affects 1 to 10 users in 100)
često (javlja se kod 1 do 10 korisnika na 100)
common (affects 1 to 10 users in 100)
često (javlja se u 1 do 10 na 100 korisnika)
common (affects 1 to 10 users in 100)
često (pojavljuju se kod 1 do 10 na 100 bolesnika)
common (affects 1 to 10 users in 100)
često (pojavljuju se u 1 do 10 na 100 korisnika)
Common (affects 1 to 10 users in 100) side effects, which were not severe, include: voice changes and hoarseness.
Česte (javljaju se u 1 do 10 na 100 korisnika) nuspojave koje nisu bile teške uključuju: promjene glasa i promuklost.
Common (affects 1 to 10 users in 100):
Često (javlja se u 1 do 10 korisnika na 100):
Common (affects 1 to 10 users in 100):
Često (pogađa 1 do 10 korisnika na 100):
Common (affects 1 to 10 users in 100):
Često (zahvaća 1 do 10 na 100 korisnika):
Common (affects less than 1 in 10 patients)
Česte (javljaju se u manje od 1 na 10 bolesnika)
Common (affects less than 1 in 10 people)
Često (pojavljuje se u manje od 1 na 10 osoba)
Common (can occur in less than 1 in 10 but in more than 1 in 100 patients treated): Flaking, peeling, dry skin
Česte (mogu nastati u manje od 1 na 10 ali u više od 1 na 100 liječenih bolesnika): perutanje, ljuštenje, suha koža
Common (children less
često (u djece mlađe
Common (may affect 1 in 10 people):
Česte (mogu se javiti u 1 na 10 osoba):
Common (may affect 1 in 10 people): diarrhoea
Često (mogu se javiti u 1 na 10 osoba): proljev
Common (may affect 1 to 10 patients in 100)
često (mogu se javiti u 1 do 10 na 100 bolesnika)
Common (may affect 1 to 10 users in 100 people)
Često (mogu se javiti u 1 do 10 korisnika na 100)
Common (may affect 1 to 10 users in 100)
Često (mogu se javiti u 1 do 10 korisnika na 100)
Common (may affect less than 1 in 10 people)
Često (pojavljuje se u manje od 1 na 10 osoba)
Common (may affect more than 1 in 100 people)
Često (mogu se javiti u više od 1 na 100 osoba)
Common (may affect more than 1 user in 100) are:
Česte nuspojave (mogu se javiti u više od 1 korisnika na 100):
Common (may affect up to 1 in 10 infants)
Često (mogu se javiti u do 1 na 10 dojenčadi)
Common (may affect up to 1 in 10 people ):
Česte (mogu se javiti u do 1 na 10 osoba):
Common (may affect up to 1 in 10 people)
Česte (mogu javiti u manje od 1 na 10 osoba)
Common (may affect up to 1 in 10 people)
Česte (mogu se javiti kod jedne od 10 osoba)
Common (may affect up to 1 in 10 people)
Česte (mogu se javiti u 1 do 10 na 100 korisnika)
Common (may affect up to 1 in 10 people)
Česte (mogu se javiti u do 1 na 10 bolesnika)
Common (may affect up to 1 in 10 people)
Česte (mogu se javiti u najviše 1 na 10 osoba)
Common (may affect up to 1 in 10 people)
Česte (mogu zahvatiti do 1 od 10 korisnika)
Common (may affect up to 1 in 10 people)
Česte (može se javiti u 1 do 10 na 100 korisnika)
Common (may affect up to 1 in 10 people)
Često (mogu se javiti kod do 1 na 10 osoba)
Common (may affect up to 1 in 10 people)
Često (mogu se javiti u do 1 na 10 osoba):
Common (may affect up to 1 in 10 people)
Često (može se javiti kod do 1 na 10 osoba)
Common (may affect up to 1 in 10 people)
Često (može se javiti u manje od 1 na 10 ljudi)
Common (may affect up to 1 in 10 people)
Često (može se javiti u manje od 1 na 10 osoba)
Common (may affect up to 1 in 10 people)
Često (pojavljuju se u 1 na 10 osoba)
common (may affect up to 1 in 10 people)
često (mogu se javiti do 1 od 10 osoba)
Common (may affect up to 1 in 10 people)
često (mogu se javiti u do 1 na 10 ljudi)
common (may affect up to 1 in 10 people)
često (mogu se javiti u do 1 na 10 osoba)
common (may affect up to 1 in 10 people)
često (mogu se pojaviti u do 1 na 10 osoba)
Common (may affect up to 1 in 10 people) blurred vision, low blood pressure, nosebleed, vomiting, increased or abnormal uterine bleeding, swelling of the face, acid reflux, migraine, irregular heartbeat and fainting.
Često (mogu se javiti u do 1 na 10 osoba): zamagljen vid, nizak krvni tlak, krvarenje iz nosa, povraćanje, pojačano ili neuobičajeno krvarenje iz maternice, oticanje lica, refluks kiseline, migrena, nepravilno kucanje srca i nesvjestica.
Common (may affect up to 1 in 10 people) flu-like symptoms, including fever, shaking and shivering, feeling of discomfort, fatigue, bone pain and aching muscles and joints.
Česte (mogu se javiti kod manje od 1 na 10 osoba) simptomi nalik gripi, uključujući vrućicu, tresavicu i drhtanje, osjećaj nelagode, umor, bol u kostima, mišićima i zglobovima.
Common (may affect up to 1 in 10 people) headache, back pain, muscle aches, pain in arms and legs, facial flushing, nasal congestion, indigestion and reflux.
Često (mogu se javiti kod do 1 na 10 osoba) glavobolja, bol u leđima, bol u mišićima, bol u rukama i nogama, crvenilo lica praćeno osjećajem užarenosti, začepljenost nosa, probavne tegobe i refluks
Common (may affect up to 1 in 10 people) headache, back pain, muscle aches, pain in arms and legs, facial flushing, nasal congestion, indigestion and reflux.
Često (mogu se javiti kod do 1 na 10 osoba) glavobolja, bol u leđima, bol u mišićima, bol u rukama i nogama, crvenilo lica praćeno osjećajem užarenosti, začepljenost nosa, probavne tegobe i refluks.
Common (may affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating fats and early in treatment, temporary increases in liver enzymes; increases in the level of sugars in the blood and urine; increases in levels of uric acid and creatine phosphokinase in the blood; feeling more hungry; dizziness; restlessness; tremor; unusual movements (dyskinesias); constipation; dry mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling of the hands, ankles or feet; fever; joint pain; and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males.
Česte nuspojave (mogu zahvatiti do 1 na 10 osoba) uključuju promjene u razinama nekih krvnih stanica, masnoća u krvotoku te u ranoj fazi liječenja i privremeni porast razine jetrenih enzima; porast razina šećera u krvi i mokraći; porast razina mokraćne kiseline i kreatin fosfokinaze u krvi; osjećaj povećane gladi; omaglicu; nemir; tremor; neuobičajene pokrete (diskineziju); konstipaciju; suha usta; osip; gubitak snage; umor u ekstremitetima; retenciju vode koja uzrokuje oticanje šaka, gležnjeva ili stopala; vrućicu; bol u zglobovima te poremećaje seksualne funkcije poput smanjenog libida u muškaraca ili žena ili erektilnu disfunkciju u muškaraca.
Common (may affect up to 1 in 10 people) side effects are:
Česte (mogu se javiti kod do 1 na10 osoba) nuspojave su:
Common (may affect up to 1 in 10 people) side effects:
Česte nuspojave (mogu se javiti u manje od 1 na 10 osoba):
Common (may affect up to 1 in 10 people) side effects: feeling sick (nausea), vomiting, a burning sensation in your stomach, diarrhoea, bloating, stomach ache and bowel pain, gas, a decreased appetite and low blood calcium.
Česte (mogu se javiti u manje od 1 na 10 osoba) nuspojave: mučnina, povraćanje, žarenje u želucu, proljev, nadutost, bol u želucu i crijevima, vjetrovi, smanjen apetit i nizak kalcij u krvi.
Common (may affect up to 1 in 10 people).
Često (mogu se javiti u najviše 1 od 10 osoba).
Common (may affect up to 1 in 10 people):
Česte (mogu se pojaviti kod do 1 od 10 osoba)
Common (may affect up to 1 in 10 people):
Česte (mogu se pojaviti kod do 1 od 10 osoba):
Common (may affect up to 1 in 10 people):
Česte mogu se javiti u manje od 1 na 10 osoba):
Common (may affect up to 1 in 10 people):
Česte nuspojave (mogu se javiti do 1 na 10 osoba):
Common (may affect up to 1 in 10 people):
Česte nuspojave (mogu se javiti u do 1 na 10 osoba):
Common (may affect up to 1 in 10 people):
Čestima (mogu se javiti u do 1 na 10 osoba):
Common (may affect up to 1 in 10 people):
Često (javljaju se kod manje od 1 na 10 osoba):
Common (may affect up to 1 in 10 people):
Često (javljaju se u 1 korisnika na 10):
Common (may affect up to 1 in 10 people):
Često (javljaju se u najviše 1 na 10 osoba):
Common (may affect up to 1 in 10 people):
Često (mogu se javiti do 1 od 10 osoba):
Common (may affect up to 1 in 10 people):
Često (mogu se javiti kod manje od 1 na 10 osoba):
Common (may affect up to 1 in 10 people):
Često (mogu se pojaviti u do 1 na 10 osoba)
Common (may affect up to 1 in 10 people):
Često (može se javiti do 1 na 10 osoba):
Common (may affect up to 1 in 10 people):
Često (može se javiti kod manje od 1 na 10 osoba):
Common (may affect up to 1 in 10 people): a metallic taste (taste disturbance).
Često (mogu se javiti u do 1 na 10 osoba): metalni okus (poremećaj okusa).
Common (may affect up to 1 in 10 people): abdominal pain, indigestion, diarrhoea, nausea
često (mogu se javiti u do 1 na 10 osoba): bolove u trbuhu, probavne smetnje, proljev, mučninu
Common (may affect up to 1 in 10 people): bruising or bleeding for longer than usual if you hurt yourself - these may be signs of a low blood platelet count (thrombocytopenia).
Česte (mogu se javiti kod do 1 na 10 osoba): modrice ili krvarenje koji traju dulje od onih koji se obično javljaju nakon ozljede - to može značiti da imate nizak broj krvnih pločica (trombocitopenija)
Common (may affect up to 1 in 10 people): diarrhoea, abdominal pain, indigestion, flatulence
Često (mogu se javiti u do 1 na 10 osoba): proljev, bol u trbuhu, probavne tegobe, vjetrovi
Common (may affect up to 1 in 10 people): diarrhoea, abdominal pain, indigestion, flatulence
Često (mogu se javiti u manje od 1 na 10 osoba): proljev, bol u trbuhu, probavne tegobe, vjetrovi
Common (may affect up to 1 in 10 people): dizziness, feeling sick/vomiting, and fatigue and blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase enzyme).
Često (mogu se javiti u manje od 1 na 10 osoba): omaglica, mučnina/povraćanje i umor; krvne pretrage mogu pokazati povišene razine enzima specifičnog za mišićnu i srčanu funkciju (enzim kreatin kinaza).
Common (may affect up to 1 in 10 people): dizziness, headache, trembling that cannot be controlled, metallic taste, low blood glucose.
često (mogu se javiti u 1 na 10 osoba): omaglica, glavobolja, nekontrolirano drhtanje, metalni okus, niska razina glukoze u krvi.
Common (may affect up to 1 in 10 people): elevated levels of some blood enzymes.
Često (mogu se javiti do 1 na 10 osoba): povišene razine nekih krvnih enzima
Common (may affect up to 1 in 10 people): feeling sick, heartburn and discomfort in swallowing (inflammation of your gullet/ food pipe)
Česte (mogu se javiti kod manje od 1 na 10 osoba): mučnina, žgaravica i nelagoda pri gutanju (upala jednjaka)